. 2021 Jun 23;31(14):R918–R929. doi: 10.1016/j.cub.2021.06.049

Table 1.

SARS-CoV-2 variants of concern and variants of interest.

Pango lineage	Nextstrain clade⁸	First detection location	VOI or VOC	WHO⁷¹ designation	Mutations of interest on S protein	Observed clinical effect
Pango lineage	Nextstrain clade⁸	First detection location	VOI or VOC	WHO⁷¹ designation	Mutations of interest on S protein	Transmissibility	Virulence	Antigenicity
B.1.1.7	20I/501Y.V1	United Kingdom	VOC	Alpha	N501Y, E484K^∗, P681H, D614G	50–100% higher²	39–72% more lethal⁴¹	No impact on NBA Minimal impact on NBS^a
B.1.351	20H/501Y.V2	South Africa	VOC	Beta	N501Y, K417N, E484K, D614G	20–113% higher⁷²	–	Moderately reduced NBA^a Reduced NBS^a
P.1	20J/501Y.V3	Brazil/Japan	VOC	Gamma	N501Y, K417T, E484K, D614G	70–140% higher, evades immunity 21–46% more⁵	20–90% more lethal⁵	Moderately reduced NBA^a Reduced NBS^a
B.1.427 and B.1.429	21C/S:452R	United States (California)	VOI	Epsilon	L452R, D614G	18–22% higher⁷³	–	Moderately reduced NBA^a Reduced NBS^a
B.1.525	21D	United States (New York)/Nigeria	VOI	Eta	A67V, E484K, D614G, Q677H, F888L	–	–	Potentially reduced NBA^a Potentially reduced NBS^a
B.1.526	21F	United States (New York)	VOI	Iota	L5F^∗, T95I, D253G, S477N^∗, E484K, D614G, A701V^∗	–	–	Moderately reduced NBA^a Reduced NBS^a
B.1.617.1	21B/S:154K	India	VOI	Kappa	(T95I), G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H	Secondary attack rates similar to B.1.1.7⁷⁴	–	Potentially reduced NBA^a Potentially reduced NBS^a
B.1.617.2	21A/S:478K	India	VOC	Delta	T19R, G142D^∗, 156del, 157del, R158G, L452R, T478K, D614G, P681R, D950N	Secondary attack rates higher than B.1.1.7; household transmission 64% higher than B.1.1.7 (26–113% higher)⁷⁴	–	Potentially reduced NBA^a Potentially reduced NBS^a
B.1.617.3	20A	India	VOI		T19R, G142D, L452R, E484Q, D614G, P681R, D950N	–	–	Potentially reduced NBA^a Potentially reduced NBS^a
P.2	20J	Brazil	VOI	Zeta	E484K, D614G, V1176F	–	–	Potentially reduced NBA^a Reduced NBS^a

Here we have used the variant classification of the Centre for Disease Control of the United States and modified from the CDC data table, which lists additional mutations and information about clinical effects^a. Nextstrain clade names start with the year of origin and distinguish lineages that reach a global frequency of 20%, so the name of a lineage can change if it increases in frequency⁸. NBA: Neutralization by antibodies (monoclonal antibodies in therapeutic use); NBS: Neutralization by convalescent and/or post-vaccination sera (variant relative to non-variant). VOI and VOC designations vary over time (e.g. B.1.427 and B.1.429 were previously designated as VOC by the CDC^a, accessed 13 June 2021) and by country (e.g. Canada designates the entire B.1.617 clade as a VOC^b) because of different evaluations of the existing evidence.

^∗

Mutation detected in some sequences within the lineage. Ranges give 95% confidence intervals or credible intervals, except for the transmission rate of B.1.1.7 (a consensus estimate across models²) and for P.1 (50% Bayesian credible intervals).

https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html; ‘moderate’ includes modest decreases and/or cases where alternative antibody treatments remain available.

https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/testing-diagnosing-case-reporting/sars-cov-2-variants-national-definitions-classifications-public-health-actions.html; (all accessed 2 July 2021).